The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005
December 12, 2022: Biosergen AB (“Biosergen” or the “Company”) today announced that the first volunteer in the MAD part of the Phase I study has been dosed with the Company’s proprietary antifungal drug candidate BSG005.Biosergen has enrolled the first subjects into the MAD part of the Phase I trial of BSG005. The subjects will be part of a first cohort of total six healthy volunteers. The successful completion of the first MAD cohort part and the Phase I trial will be a major milestone for Biosergen, as it will underline the safety of BSG005. From the SAD part we know, that BSG005 has